




DESCRIPTION	
Species Reactivity	Human
Specificity	Detects human IL-2 in direct ELISAs and Western blots. In direct ELISAs, greater than 50% cross-reactivity with recombinant rabbit IL-2 is observed and less than 20% cross-reactivity with recombinant bovine IL-2, recombinant mouse IL-2 and recombinant rat IL-2 is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	<i>E. coli</i> -derived recombinant human IL-2 Ala21-Thr153 Accession # P60568
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

APPLICATIONS							
Please Note: Optimal dilutions should be determined by each laboratory for each application. <i>General Protocols</i> are available in the <i>Technical Information</i> section on our website.							
	<table border="1"> <thead> <tr> <th>Recommended Concentration</th> <th>Sample</th> </tr> </thead> <tbody> <tr> <td>0.5 µg/mL</td> <td>See Below</td> </tr> <tr> <td>5-15 µg/mL</td> <td>See Below</td> </tr> </tbody> </table>	Recommended Concentration	Sample	0.5 µg/mL	See Below	5-15 µg/mL	See Below
Recommended Concentration	Sample						
0.5 µg/mL	See Below						
5-15 µg/mL	See Below						
Western Blot	See Below						
Immunocytochemistry	See Below						
Neutralization	Measured by its ability to neutralize IL-2-induced proliferation in the CTLL-2 mouse cytotoxic T cell line. Gearing, A.J.H. and C.B. Bird (1987) in <i>Lymphokines and Interferons, A Practical Approach</i> . Clemens, M.J. <i>et al.</i> (eds): IRL Press. 276. The Neutralization Dose (ND ₅₀) is typically ≤0.15 µg/mL in the presence of 2 ng/mL Recombinant Human IL-2.						
ELISA	This antibody functions as an ELISA detection antibody when paired with Mouse Anti-Human IL-2 Monoclonal Antibody (Catalog # MAB2021). <i>This product is intended for assay development on various assay platforms requiring antibody pairs. We recommend the Human IL-2 DuoSet ELISA Kit (Catalog # DY202) for convenient development of a sandwich ELISA or the Human IL-2 Quantikine ELISA Kit (Catalog # D2050) for a complete optimized ELISA.</i>						

DATA	
<p>Western Blot</p>  <p>Detection of Human IL-2 by Western Blot. Western blot shows lysates of monensin treated human peripheral blood mononuclear cells (PBMCs) with no additional treatment (-) or additionally treated (+) with 0.5µg/mL calcium ionomycin (Iono) and 50ng/mL PMA overnight. PVDF membrane was probed with 0.5 µg/mL of Goat Anti-Human IL-2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-202-NA) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for IL-2 at approximately 14 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.</p>	<p>Immunocytochemistry</p>  <p>IL-2 in Human PBMCs. IL-2 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) stimulated with PMA, ionomycin, and monensin using Goat Anti-Human IL-2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-202-NA) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (yellow; Catalog # NL001) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Non-adherent Cells.</p>



PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Interleukin-2 (IL-2) is a O-glycosylated, four α -helix bundle cytokine that has potent stimulatory activity for antigen-activated T cells. It is expressed by CD4⁺ and CD8⁺ T cells, $\gamma\delta$ T cells, B cells, dendritic cells, and eosinophils (1 - 3). Mature human IL-2 shares 56% and 66% aa sequence identity with mouse and rat IL-2, respectively. Human and mouse IL-2 exhibit cross-species activity (4). The receptor for IL-2 consists of three subunits that are present on the cell surface in varying preformed complexes (5 - 7). The 55 kDa IL-2 R α is specific for IL-2 and binds with low affinity. The 75 kDa IL-2 R β , which is also a component of the IL-15 receptor, binds IL-2 with intermediate affinity. The 64 kDa common gamma chain γc /IL-2 R γ , which is shared with the receptors for IL-4, -7, -9, -15, and -21, does not independently interact with IL-2. Upon ligand binding, signal transduction is performed by both IL-2 R β and γc . IL-2 is best known for its autocrine and paracrine activity on T cells. It drives resting T cells to proliferate and induces IL-2 and IL-2 R α synthesis (1, 2). It contributes to T cell homeostasis by promoting the Fas-induced death of naïve CD4⁺ T cells but not activated CD4⁺ memory lymphocytes (8). IL-2 plays a central role in the expansion and maintenance of regulatory T cells, although it inhibits the development of Th17 polarized cells (9 - 11). Thus, IL-2 may be a key cytokine in the natural suppression of autoimmunity (12, 13).

References:

1. Ma, A. *et al.* (2006) *Annu. Rev. Immunol.* **24**:657.
2. Gaffen, S.L. and K.D. Liu (2004) *Cytokine* **28**:109.
3. Taniguchi, T. *et al.* (1983) *Nature* **302**:305.
4. Mosmann, T.R. *et al.* (1987) *J. Immunol.* **138**:1813.
5. Liparoto, S.F. *et al.* (2002) *Biochemistry* **41**:2543.
6. Wang, X. *et al.* (2005) *Science* **310**:1159.
7. Bodnar, A. *et al.* (2008) *Immunol. Lett.* **116**:117.
8. Jaleco, S. *et al.* (2003) *J. Immunol.* **171**:61.
9. Malek, T.R. (2003) *J. Leukoc. Biol.* **74**:961.
10. Laurence, A. *et al.* (2007) *Immunity* **26**:371.
11. Kryczek, I. *et al.* (2007) *J. Immunol.* **178**:6730.
12. Afzali, B. *et al.* (2007) *Clin. Exp. Immunol.* **148**:32.
13. Fehervari, Z. *et al.* (2006) *Trends Immunol.* **27**:109.